What’s New in MS Research – November 2023

Milan, Italy served as the setting for cutting-edge science and high hopes last month, when multiple sclerosis (MS) researchers and clinicians from around the world gathered there in October for MSMilan2023, the 9th joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

Read News Article

What’s New in MS Research – September 2023

This edition of “What’s New in MS Research” opens with a pair of “firsts:” the first listing of multiple sclerosis (MS) therapies on the World Health Organization’s List of Essential Medicines and the first United States Food and Drug Administration (FDA) approval of a biosimilar therapy for the long-term treatment of MS.

Read News Article

What’s New in MS Research – July 2023

More than 1,800 multiple sclerosis (MS) researchers, clinicians, and advocates recently convened at the base of the Rocky Mountains for high-level discussions on the latest findings on the potential causes, impact, diagnosis, and management of MS.

Read News Article

What’s New in MS Research – May 2023

Multiple sclerosis (MS) clinicians and research were well represented when neurologists from across the country and around the world gathered in Boston in April for the 75th Annual Meeting of the American Academy of Neurology (AAN). Indeed, findings from more than 270 studies on various aspects of MS were presented at the meeting.

Read News Article

What’s New in MS Research – January 2023

The studies featured in this edition of “What’s New in MS Research” speak to progress made and progress awaited. We start out by announcing two new disease-modifying therapies that are or soon will be available through one’s healthcare provider.

Read News Article

What’s New in MS Research – November 2022

Experts in every aspect of multiple sclerosis (MS) gathered in Amsterdam, The Netherlands, in late October 2022 to unveil research results and share ideas at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). With more than 1,200 bridges, the Dutch capital was an appropriate location for a meeting dedicated to connecting the findings from laboratory research and clinical trials to enhancements in patient care.

Read News Article

What’s New in MS Research – September 2022

If there’s one theme that emerges from the study findings that follow, it’s how much people with multiple sclerosis (MS) can do to enhance their health and wellbeing. We know that can be a challenging task, as many aspects of the disease and its course remain beyond a person’s control. Nonetheless, the research summarized here provides abundant reason for encouragement.

Read News Article